Drug profile · INN
dasatinib (anhydrous)
SPRYCEL
dasatinib (anhydrous) (SPRYCEL) is a bcr/abl fusion protein inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EA02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — dasatinib (anhydrous)
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
dasatinib (anhydrous) (SPRYCEL) is a bcr/abl fusion protein inhibitor.
Key facts
INN dasatinib (anhydrous)
Brand SPRYCEL
Mechanism Bcr/Abl fusion protein inhibitor
Target Bcr/Abl fusion protein
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EA02
Mechanism of action
Bcr/Abl fusion protein inhibitor
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dasatinib (anhydrous)?
dasatinib (anhydrous) (SPRYCEL) is a bcr/abl fusion protein inhibitor.
What is the brand name for dasatinib (anhydrous)?
SPRYCEL is a marketed brand name for dasatinib (anhydrous). Check FDA Drugs@FDA for the current US label holder and prescribing information.